{"id":67217,"date":"2026-06-03T19:20:55","date_gmt":"2026-06-03T11:20:55","guid":{"rendered":"https:\/\/flcube.com\/?p=67217"},"modified":"2026-06-03T19:20:56","modified_gmt":"2026-06-03T11:20:56","slug":"legend-biotechs-in-vivo-car-t-therapy-lb2501-shows-100-response-rate-in-relapsed-refractory-b-cell-lymphoma-with-no-serious-safety-events","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67217","title":{"rendered":"Legend Biotech&#8217;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Legend Biotech Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LEGN:NASDAQ\">NASDAQ: LEGN<\/a>) announced <strong>preliminary clinical data<\/strong> for <strong>LB2501<\/strong>, its investigational <strong>first-in-class CD19\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy<\/strong>, demonstrating a <strong>100% objective response rate (ORR)<\/strong> and <strong>83.3% complete response (CR) rate<\/strong> in patients with <strong>relapsed or refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The novel <strong>off-the-shelf, single intravenous infusion<\/strong> approach generates functional CAR-T cells directly within the patient&#8217;s body, eliminating the need for complex ex vivo manufacturing processes that have historically limited CAR-T accessibility and scalability.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-patient-population\" class=\"wp-block-heading\">Clinical Trial Design &amp; Patient Population<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase I<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL)<\/td><\/tr><tr><td><strong>Total Patients<\/strong><\/td><td>12 patients across two dose levels (DL1, DL2)<\/td><\/tr><tr><td><strong>Presentation Venue<\/strong><\/td><td>2026 European Hematology Association (EHA) Annual Congress<\/td><\/tr><tr><td><strong>Treatment Regimen<\/strong><\/td><td>Single intravenous infusion (off-the-shelf)<\/td><\/tr><tr><td><strong>Therapy Class<\/strong><\/td><td>In vivo CAR-T cell generation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-efficacy-results-dose-level-2-dl2-cohort\" class=\"wp-block-heading\">Efficacy Results \u2013 Dose Level 2 (DL2) Cohort<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Patients<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td>100%<\/td><td>6\/6<\/td><\/tr><tr><td><strong>Complete Response Rate (CR)<\/strong><\/td><td>83.3%<\/td><td>5\/6<\/td><\/tr><tr><td><strong>Partial Response Rate (PR)<\/strong><\/td><td>16.7%<\/td><td>1\/6<\/td><\/tr><tr><td><strong>Clinical Significance<\/strong><\/td><td>Exceptional response rates in heavily pretreated R\/R B-NHL population<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pharmacokinetic-amp-durability-data\" class=\"wp-block-heading\">Pharmacokinetic &amp; Durability Data<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>In Vivo Expansion<\/strong>: Dose-dependent CAR-T cell expansion observed in peripheral blood<\/li>\n\n\n\n<li><strong>Persistence<\/strong>: CAR-T cells detectable for up to <strong>116 days<\/strong> post-infusion<\/li>\n\n\n\n<li><strong>Manufacturing Advantage<\/strong>: Eliminates need for leukapheresis, ex vivo manipulation, and cryopreservation<\/li>\n\n\n\n<li><strong>Scalability<\/strong>: True off-the-shelf product enables immediate treatment availability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-safety-profile\" class=\"wp-block-heading\">Safety Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Safety Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Dose-Limiting Toxicities (DLTs)<\/strong><\/td><td>None reported<\/td><\/tr><tr><td><strong>Serious Adverse Events (SAEs)<\/strong><\/td><td>None reported<\/td><\/tr><tr><td><strong>Treatment-Related Deaths<\/strong><\/td><td>None reported<\/td><\/tr><tr><td><strong>Overall Tolerability<\/strong><\/td><td>Favorable safety profile across both dose levels<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-innovative-technology-platform\" class=\"wp-block-heading\">Innovative Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Targeting<\/strong>: Simultaneous CD19\/CD20 recognition reduces antigen escape risk<\/li>\n\n\n\n<li><strong>In Vivo Generation<\/strong>: mRNA-LNP or viral vector platform enables direct CAR-T cell production in patient<\/li>\n\n\n\n<li><strong>First-in-Class Potential<\/strong>: Represents novel therapeutic modality distinct from traditional CAR-T approaches<\/li>\n\n\n\n<li><strong>Accessibility<\/strong>: Addresses key limitations of current CAR-T therapies including manufacturing delays and cost barriers<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-legend-biotech\" class=\"wp-block-heading\">Strategic Implications for Legend Biotech<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Success validates Legend&#8217;s in vivo CAR-T technology platform<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: First-mover advantage in in vivo CAR-T space for hematological malignancies<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong>: Addresses large R\/R B-NHL market with significant unmet need<\/li>\n\n\n\n<li><strong>Global Development<\/strong>: Strong preliminary data supports rapid advancement to pivotal trials<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Technology platform potentially applicable to other hematological and solid tumor indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-analysis\" class=\"wp-block-heading\">Market Impact Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Paradigm Shift<\/strong>: Could transform CAR-T from complex cellular therapy to simple intravenous infusion<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: Dramatically improves accessibility by eliminating manufacturing constraints<\/li>\n\n\n\n<li><strong>Healthcare Economics<\/strong>: Potential for reduced overall treatment costs despite premium pricing<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Challenges traditional ex vivo CAR-T products and bispecific antibodies<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Exceptional efficacy and safety data may support accelerated approval strategies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-considerations\" class=\"wp-block-heading\">Commercial Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy<\/strong>: Premium pricing justified by curative potential and simplified administration<\/li>\n\n\n\n<li><strong>Market Penetration<\/strong>: Immediate availability could capture patients currently excluded from CAR-T due to manufacturing delays<\/li>\n\n\n\n<li><strong>Infrastructure Requirements<\/strong>: Minimal specialized center requirements compared to traditional CAR-T<\/li>\n\n\n\n<li><strong>Global Reach<\/strong>: Scalable manufacturing enables worldwide distribution unlike patient-specific products<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for LB2501. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Legend-Biotech-Announces-Late-Breaking-Oral-Presentation-at-EHA-2026-Showcasing-Initial-Phase-1-In-Vivo-CAR-T-Data-with-LB2501-in-Non-Hodgkin-Lymphoma-NHL.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL).\"><\/object><a id=\"wp-block-file--media-1c0eaaa7-31fc-475f-adcd-01d9c322177e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Legend-Biotech-Announces-Late-Breaking-Oral-Presentation-at-EHA-2026-Showcasing-Initial-Phase-1-In-Vivo-CAR-T-Data-with-LB2501-in-Non-Hodgkin-Lymphoma-NHL.pdf\">Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/Legend-Biotech-Announces-Late-Breaking-Oral-Presentation-at-EHA-2026-Showcasing-Initial-Phase-1-In-Vivo-CAR-T-Data-with-LB2501-in-Non-Hodgkin-Lymphoma-NHL.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1c0eaaa7-31fc-475f-adcd-01d9c322177e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\/CD20&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,21,17,112,873],"class_list":["post-67217","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-car-t","tag-clinical-trial-results","tag-legend-biotech","tag-nasdaq-legn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Legend Biotech&#039;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy, demonstrating a 100% objective response rate (ORR) and 83.3% complete response (CR) rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67217\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legend Biotech&#039;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events\" \/>\n<meta property=\"og:description\" content=\"Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy, demonstrating a 100% objective response rate (ORR) and 83.3% complete response (CR) rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67217\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T11:20:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-03T11:20:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67217#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67217\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Legend Biotech&#8217;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\\\/Refractory B-Cell Lymphoma with No Serious Safety Events\",\"datePublished\":\"2026-06-03T11:20:55+00:00\",\"dateModified\":\"2026-06-03T11:20:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67217\"},\"wordCount\":541,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"CAR-T\",\"Clinical trial results\",\"Legend Biotech\",\"NASDAQ: LEGN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67217#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67217\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67217\",\"name\":\"Legend Biotech's In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\\\/Refractory B-Cell Lymphoma with No Serious Safety Events - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-03T11:20:55+00:00\",\"dateModified\":\"2026-06-03T11:20:56+00:00\",\"description\":\"Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\\\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy, demonstrating a 100% objective response rate (ORR) and 83.3% complete response (CR) rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R\\\/R B-NHL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67217#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67217\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67217#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legend Biotech&#8217;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\\\/Refractory B-Cell Lymphoma with No Serious Safety Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Legend Biotech's In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events - Insight, China&#039;s Pharmaceutical Industry","description":"Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy, demonstrating a 100% objective response rate (ORR) and 83.3% complete response (CR) rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67217","og_locale":"en_US","og_type":"article","og_title":"Legend Biotech's In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events","og_description":"Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy, demonstrating a 100% objective response rate (ORR) and 83.3% complete response (CR) rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL).","og_url":"https:\/\/flcube.com\/?p=67217","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-03T11:20:55+00:00","article_modified_time":"2026-06-03T11:20:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67217#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67217"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Legend Biotech&#8217;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events","datePublished":"2026-06-03T11:20:55+00:00","dateModified":"2026-06-03T11:20:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67217"},"wordCount":541,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","CAR-T","Clinical trial results","Legend Biotech","NASDAQ: LEGN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67217#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67217","url":"https:\/\/flcube.com\/?p=67217","name":"Legend Biotech's In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-03T11:20:55+00:00","dateModified":"2026-06-03T11:20:56+00:00","description":"Legend Biotech Corporation (NASDAQ: LEGN) announced preliminary clinical data for LB2501, its investigational first-in-class CD19\/CD20 dual-targeting in vivo chimeric antigen receptor (CAR)-T therapy, demonstrating a 100% objective response rate (ORR) and 83.3% complete response (CR) rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67217#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67217"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67217#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Legend Biotech&#8217;s In Vivo CAR-T Therapy LB2501 Shows 100% Response Rate in Relapsed\/Refractory B-Cell Lymphoma with No Serious Safety Events"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67217"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67217\/revisions"}],"predecessor-version":[{"id":67221,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67217\/revisions\/67221"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}